Interleukin-6 Inhibition with Ziltivekimab for Atherosclerotic Disease: Clinical Trial Evidence and Translational Insights

Highlights

  • Ziltivekimab robustly lowers inflammatory biomarkers including free interleukin-6 and high-sensitivity C-reactive protein (hsCRP) in patients with atherosclerosis and chronic kidney disease (CKD).
  • Phase 2 trials (RESCUE and RESCUE-2) demonstrated dose-dependent biomarker reductions, improvements in neutrophil-lymphocyte ratio (NLR), and a favorable safety profile.
  • The pivotal ZEUS trial involving 6376 patients revealed that despite profound biomarker suppression, ziltivekimab did not reduce major adverse cardiovascular events (MACE) compared with placebo.
  • The dissociation between biomarker modulation and clinical events underscores current knowledge gaps in targeting IL-6 for cardiovascular risk reduction and nuances of residual inflammatory risk.

Background

Specialty calculators

Browse calculators

For clinical reference; use professional judgment.

Comments

No comments yet. Why don’t you start the discussion?

Leave a Reply